AXIM Biotechnologies (AXIM Biotechnologies) EBIT : $-6.86 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is AXIM Biotechnologies EBIT?

AXIM Biotechnologies's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.70 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.86 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AXIM Biotechnologies's annualized ROC % for the quarter that ended in Dec. 2023 was -43.28%. AXIM Biotechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2,000.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. AXIM Biotechnologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -71.76%.

AXIM Biotechnologies EBIT Historical Data

The historical data trend for AXIM Biotechnologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXIM Biotechnologies EBIT Chart

AXIM Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-2.67

-5.97

-15.54

-4.37

-6.86

AXIM Biotechnologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-0.79	-2.67	-2.93	0.44	-1.70

Competitive Comparison of AXIM Biotechnologies's EBIT

For the Biotechnology subindustry, AXIM Biotechnologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AXIM Biotechnologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's EV-to-EBIT falls into.

AXIM Biotechnologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.86 Mil.

AXIM Biotechnologies (OTCPK:AXIM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AXIM Biotechnologies's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-3.016 * ( 1 - 0% )	/	( (6.797	+	7.141)	/ 2 )
=	-3.016	/	6.969
=	-43.28 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.044	-	1.502	-	( 0.023	-	max(0, 4.278	-	0.023	+	0.023	))
=	6.797

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.122	-	2.803	-	( 0.156	-	max(0, 5.978	-	0.156	+	0.156	))
=	7.141

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

AXIM Biotechnologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.792	/	( ( (0.318 + max(-4.186, 0))	+	(0.361 + max(-5.883, 0)) )	/	2 )
=	-6.792	/	( ( 0.318	+	0.361 )	/	2 )
=	-6.792	/	0.3395
=	-2,000.59 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(1.502	+	0.311	+	2.373)
=	-4.186

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(2.803	+	0.598	+	2.482)
=	-5.883

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

AXIM Biotechnologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-6.855	/	9.553
	=	-71.76 %

AXIM Biotechnologies EBIT Related Terms

Thank you for viewing the detailed overview of AXIM Biotechnologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

AXIM Biotechnologies (AXIM Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AXIM Biotechnologies Inc (OTCPK:AXIM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121

Website

https://www.aximbiotech.com

Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.

Executives

Kurt Phinney	officer: Chief Operating Officer	6914 MAGELLAN WAY, SARASOTA FL 34243
Peter O'rourke	director	C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001
Catalina Valencia	10 percent owner	6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Glycodots, Llc	10 percent owner	6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Juniper & Ivy Corp	10 percent owner	5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007
Huemoeller John Walter Ii	director	305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960
Blake Schroeder	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert L Cunningham	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Timothy Richard Scott	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert Malasek	officer: CFO	PO BOX 235472, ENCINITAS CA 92023
Lekhram Changoer	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Medical Marijuana, Inc.	10 percent owner	12255 CROSTHWAITE CIRCLE, POWAY CA 92064
Van Damme Philip A	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Foundation Sanammad	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
George Anastassov	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022